- Home
- MIRM vs HI Comparison
MIRM vs HI Comparison
Compare MIRM & HI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- HI
- Stock Information
- Founded
- MIRM 2018
- HI 2007
- Country
- MIRM United States
- HI United States
- Employees
- MIRM N/A
- HI N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- HI Miscellaneous manufacturing industries
- Sector
- MIRM Health Care
- HI Consumer Discretionary
- Exchange
- MIRM Nasdaq
- HI Nasdaq
- Market Cap
- MIRM 1.9B
- HI 2.1B
- IPO Year
- MIRM 2019
- HI N/A
- Fundamental
- Price
- MIRM $39.10
- HI $20.58
- Analyst Decision
- MIRM Strong Buy
- HI Buy
- Analyst Count
- MIRM 11
- HI 2
- Target Price
- MIRM $58.55
- HI $36.50
- AVG Volume (30 Days)
- MIRM 476.2K
- HI 563.9K
- Earning Date
- MIRM 05-07-2025
- HI 04-29-2025
- Dividend Yield
- MIRM N/A
- HI 4.39%
- EPS Growth
- MIRM N/A
- HI N/A
- EPS
- MIRM N/A
- HI N/A
- Revenue
- MIRM $336,888,000.00
- HI $3,116,400,000.00
- Revenue This Year
- MIRM $29.51
- HI N/A
- Revenue Next Year
- MIRM $20.27
- HI N/A
- P/E Ratio
- MIRM N/A
- HI N/A
- Revenue Growth
- MIRM 80.76
- HI 5.87
- 52 Week Low
- MIRM $23.14
- HI $18.36
- 52 Week High
- MIRM $54.23
- HI $49.95
- Technical
- Relative Strength Index (RSI)
- MIRM 34.64
- HI 37.59
- Support Level
- MIRM $37.83
- HI $20.00
- Resistance Level
- MIRM $40.32
- HI $21.76
- Average True Range (ATR)
- MIRM 2.47
- HI 1.65
- MACD
- MIRM -0.33
- HI 0.03
- Stochastic Oscillator
- MIRM 25.14
- HI 34.42
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About HI Hillenbrand Inc
Hillenbrand Inc is a U.S.-based company that operates through three segments. The Advanced Process Solutions segment designs, develops, manufactures, and services engineered industrial equipment. The Molding Technology Solutions segment offers engineered and customized systems in plastic technology and processing. Batesville designs provides, and markets funeral services and solutions.